Blueprint Medicines (FRA:2L9) Additional Paid-In Capital : €2,360.1 Mil(As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Additional Paid-In Capital?

Blueprint Medicines's quarterly additional paid-in capital declined from Sep. 2023 (€2,280.9 Mil) to Dec. 2023 (€2,268.6 Mil) but then increased from Dec. 2023 (€2,268.6 Mil) to Mar. 2024 (€2,360.1 Mil).

Blueprint Medicines's annual additional paid-in capital increased from Dec. 2021 (€1,991.5 Mil) to Dec. 2022 (€2,226.0 Mil) and increased from Dec. 2022 (€2,226.0 Mil) to Dec. 2023 (€2,268.6 Mil).

Blueprint Medicines Additional Paid-In Capital Historical Data

The historical data trend for Blueprint Medicines's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Additional Paid-In Capital Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,270.88

1,731.63

1,991.47

2,225.97

2,268.64

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,224.19	2,224.99	2,280.90	2,268.64	2,360.06

Blueprint Medicines Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Blueprint Medicines Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (FRA:2L9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines